Authors: Lovepreet Singh, Kapil Kanwar, Ajeet Pal Singh
Abstract
Proton pump inhibitors (PPIs) were clinically introduced a few years ago and have since become an important, safe, and successful treatment for a variety of corrosive-related issues. To specifically overcome these limitations, longer-acting PPIs and innovation to draw out ordinary PPI action have been created, which may improve clinical outcomes. PPIs are identified by their pharmacokinetic properties, digestion, and clinical indications that have been approved by the Food and Drug Administration (FDA). Keywords: Proton pumps inhibitors, Pharmacokinetic, Pharmacological activity, Marketed formulation.
Open full article page